Literature DB >> 18493981

IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3.

Hiromi Imamichi1, Irini Sereti, H Clifford Lane.   

Abstract

IL-15 is a member of the gamma chain-dependent cytokines and known to affect innate and CD8(+) adaptive immune responses. Despite a growing interest in the use of IL-15 as an immunotherapeutic agent, the broad spectrum of immunoregulatory functions exerted by IL-15 has not been fully elucidated. Here, we demonstrate that IL-15 increases expression of CD25 and forkhead box transcription factor P3 (FOXP3), a master transcriptional regulator of regulatory T cells, in human peripheral CD4(+)CD25(-) T cells in the absence of antigenic stimulation. Comparisons involving IL-2 and IL-7 revealed that the induction of CD25(hi) and FOXP3 expression was most prominent with IL-15 and IL-2. More modest effects were seen with IL-7. Despite levels of FOXP3 expression comparable to that of conventional regulatory T cells, cytokine-induced CD4(+)CD25(hi)FOXP3(+) cells exerted only weak suppressor activity. Thus, the current study has demonstrated that IL-15 acts as a potent inducer of CD4(+)CD25(hi)FOXP3(+) cells in the periphery, and suggests a potential role for IL-15 in blunting immune activation. This study has provided further insights into the pleiotropic nature of IL-15 beyond the regulation of CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493981      PMCID: PMC2684826          DOI: 10.1002/eji.200737607

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  54 in total

Review 1.  Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.

Authors:  S A Rosenberg
Journal:  Cancer J Sci Am       Date:  2000-02

Review 2.  Regulatory T cells in the control of immune pathology.

Authors:  K J Maloy; F Powrie
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

3.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

4.  Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.

Authors:  J A Kovacs; S Vogel; J A Metcalf; M Baseler; R Stevens; J Adelsberger; R Lempicki; R L Hengel; I Sereti; L Lambert; R L Dewar; R T Davey; R E Walker; J Falloon; M A Polis; H Masur; H C Lane
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

5.  Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation.

Authors:  I Sereti; J Gea-Banacloche; M Y Kan; C W Hallahan; H C Lane
Journal:  Clin Immunol       Date:  2000-12       Impact factor: 3.969

Review 6.  CD4+ CD25+ suppressor T cells: more questions than answers.

Authors:  Ethan M Shevach
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

7.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.

Authors:  Thomas R Malek; Aixin Yu; Vladimir Vincek; Paul Scibelli; Lin Kong
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

8.  Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.

Authors:  D Dieckmann; H Plottner; S Berchtold; T Berger; G Schuler
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.

Authors:  H Jonuleit; E Schmitt; M Stassen; A Tuettenberg; J Knop; A H Enk
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.

Authors:  J J Peschon; P J Morrissey; K H Grabstein; F J Ramsdell; E Maraskovsky; B C Gliniak; L S Park; S F Ziegler; D E Williams; C B Ware; J D Meyer; B L Davison
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  24 in total

1.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

2.  Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy.

Authors:  Yue Zhang; Lukas W Pfannenstiel; Elzbieta Bolesta; Carolina L Montes; Xiaoyu Zhang; Andrei I Chapoval; Ronald B Gartenhaus; Scott E Strome; Brian R Gastman
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

3.  Regulatory T cells limit unconventional memory to preserve the capacity to mount protective CD8 memory responses to pathogens.

Authors:  Andreia S Da Costa; Jessica B Graham; Jessica L Swarts; Jennifer M Lund
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

4.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

5.  Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development.

Authors:  Alessandra Battaglia; Alexia Buzzonetti; Cinzia Baranello; Mara Fanelli; Marco Fossati; Valentina Catzola; Giovanni Scambia; Andrea Fattorossi
Journal:  Immunology       Date:  2013-05       Impact factor: 7.397

6.  Safety and immunologic effects of IL-15 administration in nonhuman primates.

Authors:  Carolina Berger; Michael Berger; Robert C Hackman; Michael Gough; Carole Elliott; Michael C Jensen; Stanley R Riddell
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

7.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

8.  Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

Authors:  Jia Liu; Sonia Wennier; Mary Reinhard; Edward Roy; Amy MacNeill; Grant McFadden
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  Expansion of regulatory T cells from umbilical cord blood and adult peripheral blood CD4(+)CD25 (+) T cells.

Authors:  Syh-Jae Lin; Chun-Hao Lu; Dah-Chin Yan; Pei-Tzu Lee; Hsiu-Shan Hsiao; Ming-Ling Kuo
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.